Relapsed or Refractory Multiple Myeloma Clinical Trial
Official title:
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
NCT number | NCT03815383 |
Other study ID # | 0203-008 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | April 11, 2019 |
Est. completion date | April 2021 |
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | April 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Volunteered to participate in this study and signed informed consent. 2. Age 18-75 years old, male or female. 3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG diagnostic criteria 2014). 4. Patients with relapsed or refractory multiple myeloma. 5. Subjects have one or more measurable multiple myeloma lesion, must include one of the following conditions: - Serum M protein=1 g/dl(10g/L) - Urine M protein=200 mg/24h - Serum free light chain(sFLC): ?/? ratio abnormal and =10 mg/dl 6. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination. 7. At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy. 8. ECOG scores 0 - 1. 9. Normal cardiac diastolic function, left ventricular ejection fraction (LVEF) = 50% (detected by echocardiography), no serious arrhythmia. 10. No active pulmonary infections, normal pulmonary function and oxygen saturation = 92% on room air. 11. No contraindications of leukapheresis. 12. Expected survival > 12 weeks. 13. Female subjects in childbearing age, their serum or urine pregnancy test must be negative,until 7 days before cell therapy and all subjects must agree to take effective contraceptive measures during the trial. Exclusion Criteria: 1. Have a history of allergy to cellular products. 2. Any kind of these laboratory testing: including but not limited to,serum total bilirubin?1.5mg/dl, serum ALT, AST?2.5×ULN, serum creatinine?2.0mg/dl, Hb (hemoglobin)<80g/L, neutrophils<1000/mm^3, platelets?50000/mm^3 or platelet count maintained by transfusion. 3. Subjects with the clinically significant cardiovascular diseases. 4. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral ischemia or hemorrhagic disease. 5. Use any anticoagulant (except aspirin). 6. Patients requiring urgent treatment due to tumor progression or spinal cord compression. 7. Patients with active CNS involvement or clinical syndrome of MM meningeal involvement. 8. After allogeneic hematopoietic stem cell transplantation. 9. Plasma cell leukemia. 10. Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy. 11. Uncontrolled active infection. 12. Prior treatment with CAR T therapy or any other genetically modified T cell therapy. 13. Live vaccine inoculation within four weeks before enrollment. 14. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons. 15. Have a history of alcoholism, drug addiction and mental illness. 16. Participated in any other clinical trial within one month. 17. The investigators believe that there are other circumstances that are not suitable for the trial. |
Country | Name | City | State |
---|---|---|---|
China | the First Affiliated Hospital of Nanjing Medical University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital with Nanjing Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety:TEAEs | The incidence of treatment-emergent adverse events (TEAEs) | 30 days | |
Secondary | ORR | Overall response rate | 12 months | |
Secondary | PFS | Progression free survival | 6 months, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03837509 -
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05519085 -
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 3 | |
Active, not recruiting |
NCT02099539 -
QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00545519 -
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05052970 -
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
|
Phase 1 | |
Completed |
NCT03464916 -
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
|
Phase 1 | |
Recruiting |
NCT05455320 -
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
|
Phase 3 | |
Withdrawn |
NCT05408026 -
Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05652335 -
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
|
Phase 1 | |
Completed |
NCT03859427 -
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
Not yet recruiting |
NCT06375044 -
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT01866293 -
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT01058434 -
Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
|
Phase 2 | |
Recruiting |
NCT04735575 -
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06298266 -
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
|
Early Phase 1 | |
Recruiting |
NCT05572515 -
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 3 | |
Active, not recruiting |
NCT04798586 -
MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
|
Phase 1 | |
Terminated |
NCT02075021 -
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT00478777 -
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
|
Phase 3 |